Milrinone

Milrinone is a phosphodiesterase inhibitor, a cardiotonic drug with positive inotropic and vasodilating effects, which can be used to treat acute or chronic refractory congestive heart failure.

Millinone is a cardiotropic drug, belonging to phosphodiesterase inhibitors. By inhibiting phosphodiesterase, the drug can increase the concentration of cyclic adenosine phosphate and calcium in cardiomyocytes, thereby effectively strengthening myocardial contractility and increasing cardiac output, so as to exert positive muscle strength. In addition, Milrinone can also play a vasodilator role by directly acting on the small arteries.

milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival. 

Milrinone, is a medication used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance. Milrinone also works to vasodilate which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. While it has been used in people with heart failure for many years, recent studies suggest that milrinone may exhibit some negative side effects that have caused some debate about its use clinically.
Overall, milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival. 

Re na le lifeme tse ngata tsa boleng bo holimo tse nang le tšebelisano e tebileng, tse ka u fang lihlahisoa tsa boleng bo holimo le litheko tsa tlholisano. Hape re ka fana ka litheolelo bakeng sa ho reka ka bongata.'Me re sebelisana le lik'hamphani tse ngata tsa litsebi tse tsamaisang thepa, li ka isa lihlahisoa ka mokhoa o sireletsehileng le ka thelelo matsohong a hau. Nako ea ho fana e ka ba matsatsi a 3-20 ka mor'a hore ho netefatsoe tefo.

Milrinone is a PDE3 (phosphodiesterase 3) inhibitor that exhibits vasodilator and positive inotropic effects. Milrinone's positive inotropic activity can be inhibited by carbachol (sc-202092). Research indicates that Milrinone can increase platelets and enhance cAMP levels. Milrinone is an inhibitor of PDE3A and PDE3B.
Milrinone, commonly known and marketed as the drug Primacor, is a medication used in patients suffering from heart failure. Milrinone is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility. Milrinone also works to vasodilate vessels which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. Milrinone has been used in those suffering from heart failure for many years.

1. Na u feme kapa k'hamphani ea khoebo?
Re komnay e kopanyang indasteri le khoebo, ho fana ka ts'ebeletso e le 'ngoe.OEM e ka amoheloa.

2. O fana ka mehlala? Na ke mahala kapa ho feta?
Mehlala ea mahala. Tefiso ea thepa ea sampole e hloka ho lefuoa ka lehlakore la hau.

3. O na le litifikeiti tse amanang le taolo ea boleng?
Setifikeiti sa ISO 9001:2008 ho netefatsa boleng.

4. Ke fane ka eng ho fumana khotheishene?
Pls re tsebise ka mofuta oa sehlahisoa seo u se hlokang, bongata ba odara, aterese le litlhoko tse ikhethileng. Khotheishene e tla etsoa bakeng sa referense ea hau ka nako.

5. U khetha mofuta ofe oa mokhoa oa ho lefa? Ke mantsoe a mofuta ofe a amoheloang?
Melao e Amoheletsoeng ea Thomello: FOB,CFR,CIF,EXW;
Chelete ea Tefo e Amoheletsoeng: USD;
Mofuta oa Tefo o Amoheletsoeng: T/T, Western Union; Paypal, Tiisetso ea Khoebo.
Puo e Builoeng: Senyesemane.